Dyadic International logo

Dyadic InternationalNASDAQ: DYAI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 January 2008

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$30.95 M
-77%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
92%vs. sector
-69%vs. 3y high
82%vs. sector

Price

regular market | 45 min ago
$1.05-$0.01(-0.94%)

Dividend

No data over the past 3 years
$385.90 K$1.10 M
$385.90 K-$2.05 M

Analysts recommendations

Institutional Ownership

DYAI Latest News

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
globenewswire.com04 November 2024 Sentiment: -

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024.

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
globenewswire.com30 July 2024 Sentiment: POSITIVE

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024.

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
globenewswire.com28 June 2024 Sentiment: POSITIVE

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.

Dyadic to Attend Industry Events in June
globenewswire.com30 May 2024 Sentiment: NEUTRAL

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024.

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
seekingalpha.com17 May 2024 Sentiment: NEUTRAL

Dyadic International, Inc. (NASDAQ:DYAI) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 5:00 PM ET. The call will feature President & CEO Mark Emalfarb, CFO Ping Rawson, and COO Joseph Hazelton. Zacks analyst John Vandermosten will also be participating. Good evening, everyone, and welcome to the conference call. Please note that all participants are currently in a listen-only mode.

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript
Seeking Alpha28 March 2024 Sentiment: POSITIVE

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
GlobeNewsWire14 March 2024 Sentiment: POSITIVE

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
Seeking Alpha08 November 2023 Sentiment: POSITIVE

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

Dyadic to Present at Industry and Investor Events in October
GlobeNewsWire29 September 2023 Sentiment: POSITIVE

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at [email protected].

Dyadic to Present at BioProcess International
GlobeNewsWire12 September 2023 Sentiment: POSITIVE

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

What type of business is Dyadic International?

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

What sector is Dyadic International in?

Dyadic International is in the Healthcare sector

What industry is Dyadic International in?

Dyadic International is in the Biotechnology industry

What country is Dyadic International from?

Dyadic International is headquartered in United States

When did Dyadic International go public?

Dyadic International initial public offering (IPO) was on 16 January 2008

What is Dyadic International website?

https://www.dyadic.com

Is Dyadic International in the S&P 500?

No, Dyadic International is not included in the S&P 500 index

Is Dyadic International in the NASDAQ 100?

No, Dyadic International is not included in the NASDAQ 100 index

Is Dyadic International in the Dow Jones?

No, Dyadic International is not included in the Dow Jones index

When was Dyadic International the previous earnings report?

No data

When does Dyadic International earnings report?

The next expected earnings date for Dyadic International is 08 November 2024